Lebrikizumab Monotherapy for the Treatment of Moderate to Severe Atopic Dermatitis
- PMID: 37684078
- DOI: 10.1016/j.jaip.2023.06.042
Lebrikizumab Monotherapy for the Treatment of Moderate to Severe Atopic Dermatitis
Comment on
-
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources